Remdesivir Receives Emergency FDA Approval. Will Be Available This Week

On Friday May 1 Gilead’s investigational antiviral drug Remdesivir received emergency use authorization for the treatment of COVID-19. Gilead’s CEO Dan O’day indicated “We intend to get that to patients in the early part of this next week,” while on CBS’ “Face of the Nation”.

He went on to state that Gilead has donated 1.5 million vials of Remdesivir, which can treat 100,000 to 200,000 people, to the government. The federal government will distribute these treatments according to need in cities throughout the country. Treatments are expected to be in the hands of doctors and nurses in the upcoming days. According to the CDC there have been over 1.12 million confirmed cases of COVID-19 and over 65,000 deaths in the U.S.

Source

Pharma CEO says coronavirus drug remdesivir will be available this week

CDC Cases in the U.S.

Listen to Michelle Obama’s Message to Healthcare Workers During the COVID-19 Pandemic

Most Recent

Non-Small Cell Lung Cancer

Oncology

Pulmonology

Risk Stratification in Post-Surgery Non-Small Cell Lung Cancer Patients

A retrospective analysis finds that patients who undergo pneumonectomy or are aged 70 years or older after receiving neoadjuvant concurrent chemoradiation therapy experience less favorable surgical outcomes. Lung cancer, particularly stage IIIA–N2 non-small cell lung cancer (NSCLC), is one of the leading causes of cancer-related deaths worldwide. The most effective treatment approach for this type...

Non-Small Cell Lung Cancer

Oncology

Pulmonology

Postoperative Complications and Surgical Issues With Neoadjuvant Immunotherapy-Treated Lung Cancer

Neoadjuvant chemoimmunotherapy, whether compared to immunotherapy alone or in combination with apatinib, may lead to increased surgical complexity while maintaining an acceptable incidence of postoperative complications, according to the results of a retrospective study. Lung cancer, specifically non-small cell lung cancer (NSCLC), is the leading cause of cancer-related deaths worldwide, accounting for nearly 85% of...

Non-Small Cell Lung Cancer

Oncology

Pulmonology

The Impact of Kinlessness on the Survival of Lung Cancer Patients

In a retrospective study, patients without a social support network had a shorter survival rate than those with support. Non-small cell lung cancer (NSCLC) continues to be a significant health issue and is a leading cause of death in many countries. Although there are promising new treatments available for certain types of lung cancer, managing...